Compare ADMA Biologics Inc (ADMA) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $436.5 (market cap $1.98T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 929.6× ADMA Biologics Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TSM | |
|---|---|---|
Market Cap | $2.13B | $1.98T |
Sector | Health | Technology |
52-Week High | $20.38 | $477.57 |
52-Week Low | $7.60 | $227.33 |
Enterprise Value | $2.20B | $1.90T |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TSM trades at $432.57, down 0.37% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q1 2026 EPS of $3.49, beating expectations, and maintains robust profitability with a 46.5% net income margin. Revenue growth accelerated to $3.81 trillion in 2025, up from $2.89 trillion in 2024, driven by AI chip demand. Analyst consensus is strongly bullish with a $493.75 price target, and the stock is near its 52-week high.
Outlook remains positive given TSM's critical role in AI semiconductor manufacturing and consistent earnings beats, but risks include geopolitical tensions in Taiwan, valuation premiums, and competitive pressures from hyperscalers developing in-house chips. The stock's premium P/E of 39.27 requires sustained high growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
